Jens Hasskarl

Title: Jens Hasskarl: Innovator in Immunotherapy

Introduction

Jens Hasskarl is a notable inventor based in Boudry, Switzerland. He has made significant contributions to the field of immunotherapy, particularly in T cell modulation. His innovative approaches aim to enhance the efficacy of cancer treatments through advanced methodologies.

Latest Patents

Hasskarl holds a patent titled "Methods and combinations for treatment and T cell modulation." This patent focuses on methods, compositions, and uses involving immunotherapies, such as adoptive cell therapy and T cell therapy. The disclosure includes immunomodulatory compounds, including structural or functional analogs of thalidomide and inhibitors of E3-ubiquitin ligase. The methods and compositions provided aim to improve the activity, efficacy, persistence, and proliferation of T cells for adoptive cell therapy.

Career Highlights

Jens Hasskarl is associated with Juno Therapeutics GmbH, where he continues to develop innovative therapies. His work is pivotal in advancing the field of immunotherapy, particularly in the context of genetically engineered T cell therapies.

Collaborations

Hasskarl collaborates with esteemed colleagues, including Stanley R. Frankel and Michael Ports. These partnerships enhance the research and development of groundbreaking therapies in the field of immunology.

Conclusion

Jens Hasskarl's contributions to immunotherapy through his patent and work at Juno Therapeutics GmbH highlight his role as a leading innovator in the field. His efforts are paving the way for more effective cancer treatments.